You’ve probably seen compounding making headlines recently, and not for the right reasons. From so-called “personalized” GLP-1s flooding the market to telehealth startups touting hormone “rebalancing” kits, compounding has become a buzzword for companies looking to shortcut regulation. Much of the scrutiny is justified; some companies exploit compounding to bypass evidence standards or chase fast revenue. But when compounding is grounded in rigorous data, fills a real market gap, and meets a...